WO2016038625A3 - Antigènes supérieurs du papillomavirus présentant des propriétés immunologiques supérieures et vaccin les contenant - Google Patents

Antigènes supérieurs du papillomavirus présentant des propriétés immunologiques supérieures et vaccin les contenant Download PDF

Info

Publication number
WO2016038625A3
WO2016038625A3 PCT/IN2015/000355 IN2015000355W WO2016038625A3 WO 2016038625 A3 WO2016038625 A3 WO 2016038625A3 IN 2015000355 W IN2015000355 W IN 2015000355W WO 2016038625 A3 WO2016038625 A3 WO 2016038625A3
Authority
WO
WIPO (PCT)
Prior art keywords
present
superior
human papilloma
papilloma virus
provides
Prior art date
Application number
PCT/IN2015/000355
Other languages
English (en)
Other versions
WO2016038625A2 (fr
Inventor
Gaurav Gupta
Viviana Giannino
Reinhard Glueck
Original Assignee
Cadila Healthcare Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Limited filed Critical Cadila Healthcare Limited
Priority to EP15808033.3A priority Critical patent/EP3191505A2/fr
Priority to CN201580049136.4A priority patent/CN107002085A/zh
Priority to BR112017004181A priority patent/BR112017004181A2/pt
Priority to AU2015313756A priority patent/AU2015313756A1/en
Priority to CA2958222A priority patent/CA2958222A1/fr
Priority to JP2017513424A priority patent/JP2017528137A/ja
Priority to EA201790365A priority patent/EA201790365A1/ru
Publication of WO2016038625A2 publication Critical patent/WO2016038625A2/fr
Publication of WO2016038625A3 publication Critical patent/WO2016038625A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des gènes codant pour divers antigènes du papillomavirus de plusieurs sérotypes. Les gènes de la présente invention permettent de produire des particules de type virus présentant une amélioration en termes de qualité immunologique et de structure quaternaire. La présente invention concerne également une cellule hôte adaptée, de préférence P.pastoris, avec un nombre élevé de copies de gènes codant pour divers antigènes de papillomavirus de plusieurs sérotypes. La présente invention porte en outre sur un vaccin contre des antigènes du papillomavirus avec programme d'immunisation amélioré, le régime posologique du vaccin et la quantité de dose d'antigène étant réduits. La présente invention concerne également une composition de vaccin améliorée du virus du papillomavirus au moyen de levure.
PCT/IN2015/000355 2014-09-11 2015-09-11 Antigènes supérieurs du papillomavirus présentant des propriétés immunologiques supérieures et vaccin les contenant WO2016038625A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP15808033.3A EP3191505A2 (fr) 2014-09-11 2015-09-11 Antigènes supérieurs du papillomavirus présentant des propriétés immunologiques supérieures et vaccin les contenant
CN201580049136.4A CN107002085A (zh) 2014-09-11 2015-09-11 具有优异免疫学特性的优异的人乳头瘤病毒抗原和含有其的疫苗
BR112017004181A BR112017004181A2 (pt) 2014-09-11 2015-09-11 ?gene, vetor, célula hospedeira, partículas similares a vírus, vacina para vírus de papiloma humano, composição imunogênica, adjuvante, método para o preparo de uma vacina de papiloma humano, proteína de capsídeo principal e proteína hpv l1?
AU2015313756A AU2015313756A1 (en) 2014-09-11 2015-09-11 Superior human papilloma virus antigens with superior immunological properties and vaccine containing it
CA2958222A CA2958222A1 (fr) 2014-09-11 2015-09-11 Antigenes superieurs du papillomavirus presentant des proprietes immunologiques superieures et vaccin les contenant
JP2017513424A JP2017528137A (ja) 2014-09-11 2015-09-11 卓越した免疫学的特性を有する卓越したヒトパピローマウイルス抗原及びそれを含むワクチン
EA201790365A EA201790365A1 (ru) 2014-09-11 2015-09-11 Антигены вируса папилломы человека с хорошими иммунологическими свойствами и содержащая их вакцина

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2905MU2014 2014-09-11
IN2905/MUM/2014 2014-09-11

Publications (2)

Publication Number Publication Date
WO2016038625A2 WO2016038625A2 (fr) 2016-03-17
WO2016038625A3 true WO2016038625A3 (fr) 2016-04-28

Family

ID=54843870

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2015/000355 WO2016038625A2 (fr) 2014-09-11 2015-09-11 Antigènes supérieurs du papillomavirus présentant des propriétés immunologiques supérieures et vaccin les contenant

Country Status (10)

Country Link
EP (1) EP3191505A2 (fr)
JP (1) JP2017528137A (fr)
CN (1) CN107002085A (fr)
AR (1) AR101840A1 (fr)
AU (1) AU2015313756A1 (fr)
BR (1) BR112017004181A2 (fr)
CA (1) CA2958222A1 (fr)
EA (1) EA201790365A1 (fr)
MA (1) MA40624A (fr)
WO (1) WO2016038625A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117187262A (zh) * 2014-02-18 2023-12-08 上海泽润生物科技有限公司 重组人乳头瘤病毒蛋白表达
CA3002323A1 (fr) 2015-10-19 2017-04-27 Cadila Healthcare Limited Nouvel adjuvant et composition vaccinale le contenant
CN109750049B (zh) * 2017-11-07 2023-08-18 上海泽润生物科技有限公司 重组人乳头瘤病毒52亚型蛋白表达
US11946048B2 (en) 2017-11-14 2024-04-02 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Non-human papillomaviruses for gene delivery in vitro and in vivo
US11389519B2 (en) * 2018-06-11 2022-07-19 Inventprise, Llc Virus-like particle conjugates
BR102020006846A2 (pt) * 2020-04-03 2021-12-07 Imunoscan Engenharia Molecular Ltda Peptídeos sintéticos miméticos a proteína l1 do hpv, método de diagnóstico de hpv, sistema de diagnóstico de hpv, composição farmacêutica e uso dos mesmos no tratamento ou profilaxia do hpv

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997018301A1 (fr) * 1995-11-15 1997-05-22 Merck & Co., Inc. Particules synthetiques de type viral hpv11
WO1999013056A1 (fr) * 1997-09-05 1999-03-18 Medimmune, Inc. Methode de desassemblage-reassemblage in vitro de particules viroides (vlp) du papillomavirus
EP2223933A1 (fr) * 2007-11-23 2010-09-01 Shanghai Zerun Biotechnology Co., Ltd. Gènes codant pour la protéine majeure de capside l1 du virus du papillome humain
WO2012177970A1 (fr) * 2011-06-24 2012-12-27 Merck Sharp & Dohme Corp. Formulation de vaccin contre le papillomavirus comprenant un adjuvant à l'aluminium, et procédé de production correspondant
CN103667319A (zh) * 2012-09-10 2014-03-26 同济大学 抗人乳头瘤病毒的三价疫苗及其制法和用途
EP2881401A1 (fr) * 2012-07-30 2015-06-10 Kim, Hong-Jin Méthode extrêmement efficace de purification de pseudo-particules virales du papillomavirus humain

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4598201B2 (ja) * 1997-04-08 2010-12-15 メルク・シャープ・エンド・ドーム・コーポレイション 安定化ヒトパピローマウイルス製剤
MY140664A (en) * 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
MY139500A (en) * 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
CN101115766B (zh) * 2004-06-18 2013-05-08 印度免疫有限公司 用于抗人乳头瘤病毒型16的salmonella疫苗菌株的密码子经优化的hpv16l1
CN101487009B (zh) * 2008-01-15 2012-11-21 上海泽润生物科技有限公司 用毕赤酵母表达系统制备抗人乳头瘤病毒16型感染的疫苗的方法
AU2009275909A1 (en) * 2008-07-31 2010-02-04 Glaxosmithkline Biologicals S.A. Vaccine against HPV
US9566323B2 (en) * 2009-06-19 2017-02-14 Eyegene Inc. Vaccine for cervical cancer
CN102154325B (zh) * 2011-01-01 2013-08-21 上海生物制品研究所有限责任公司 针对人乳头瘤状病毒的疫苗及其制法和用途
CA2835972A1 (fr) * 2011-05-13 2012-11-22 Folia Biotech Inc. Particules pseudo-virales (vlp)et leur procede de preparation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997018301A1 (fr) * 1995-11-15 1997-05-22 Merck & Co., Inc. Particules synthetiques de type viral hpv11
WO1999013056A1 (fr) * 1997-09-05 1999-03-18 Medimmune, Inc. Methode de desassemblage-reassemblage in vitro de particules viroides (vlp) du papillomavirus
EP2223933A1 (fr) * 2007-11-23 2010-09-01 Shanghai Zerun Biotechnology Co., Ltd. Gènes codant pour la protéine majeure de capside l1 du virus du papillome humain
WO2012177970A1 (fr) * 2011-06-24 2012-12-27 Merck Sharp & Dohme Corp. Formulation de vaccin contre le papillomavirus comprenant un adjuvant à l'aluminium, et procédé de production correspondant
EP2881401A1 (fr) * 2012-07-30 2015-06-10 Kim, Hong-Jin Méthode extrêmement efficace de purification de pseudo-particules virales du papillomavirus humain
CN103667319A (zh) * 2012-09-10 2014-03-26 同济大学 抗人乳头瘤病毒的三价疫苗及其制法和用途

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
DATABASE Geneseq [online] 15 June 2007 (2007-06-15), "Human HPV11 L1 protein (wild-type).", XP002754333, retrieved from EBI accession no. GSP:AAW18632 Database accession no. AAW18632 *
DATABASE Geneseq [online] 15 June 2007 (2007-06-15), "Human HPV6 L1 protein (wild-type).", XP002754332, retrieved from EBI accession no. GSP:AAW18631 Database accession no. AAW18631 *
DATABASE Geneseq [online] 3 July 2014 (2014-07-03), "Human papillomavirus major capsid protein 16L1 (HPV16L1), SEQ: 2.", XP002754282, retrieved from EBI accession no. GSP:BBF77734 Database accession no. BBF77734 *
DATABASE Geneseq [online] 3 July 2014 (2014-07-03), "Human papillomavirus major capsid protein 18L1 (HPV18L1), SEQ: 5.", XP002754268, retrieved from EBI accession no. GSP:BBF77737 Database accession no. BBF77737 *
HENRYK MACH ET AL: "Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles (HPV VLPs)", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 95, no. 10, 1 October 2006 (2006-10-01), WASHINGTON, US, pages 2195 - 2206, XP055250213, ISSN: 0022-3549, DOI: 10.1002/jps.20696 *
MICHAEL P. MCCARTHY ET AL: "Quantitative Disassembly and Reassembly of Human Papillomavirus Type 11 Viruslike Particles In Vitro", JOURNAL OF VIROLOGY, 1 January 1998 (1998-01-01), UNITED STATES, pages 32 - 41, XP055250212, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC109346/pdf/jv000032.pdf> *
N. HANUMANTHA RAO ET AL: "Expression of codon optimized major capsid protein (L1) of human papillomavirus type 16 and 18 in Pichia pastoris; purification and characterization of the virus-like particles", VACCINE, vol. 29, no. 43, 29 July 2011 (2011-07-29), pages 7326 - 7334, XP055011829, ISSN: 0264-410X, DOI: 10.1016/j.vaccine.2011.07.071 *
QINJIAN ZHAO ET AL: "Characterization of virus-like particles in GARDASIL by cryo transmission electron microscopy", HUMAN VACCINES & IMMUNOTHERAPEUTICS, vol. 10, no. 3, 3 December 2013 (2013-12-03), US, pages 734 - 739, XP055250290, ISSN: 2164-5515, DOI: 10.4161/hv.27316 *
QINJIAN ZHAO ET AL: "Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity", VIROLOGY JOURNAL, BIOMED CENTRAL, LONDON, GB, vol. 9, no. 1, 22 February 2012 (2012-02-22), pages 52, XP021118932, ISSN: 1743-422X, DOI: 10.1186/1743-422X-9-52 *
SILVIA BOSCHI BAZAN ET AL: "Expression and characterization of HPV-16 L1 capsid protein in Pichia pastoris", ARCHIVES OF VIROLOGY ; OFFICIAL JOURNAL OF THE VIROLOGY DIVISIONOF THE INTERNATIONAL UNION OF MICROBIOLOGICAL SOCIETIES, SPRINGER-VERLAG, VI, vol. 154, no. 10, 10 September 2009 (2009-09-10), pages 1609 - 1617, XP019762201, ISSN: 1432-8798, DOI: 10.1007/S00705-009-0484-8 *
ZIJUN JIANG ET AL: "Purification and immunogenicity study of human papillomavirus 58 virus-like particles expressed in", PROTEIN EXPRESSION AND PURIFICATION, vol. 80, no. 2, 29 July 2011 (2011-07-29), pages 203 - 210, XP028312697, ISSN: 1046-5928, [retrieved on 20110729], DOI: 10.1016/J.PEP.2011.07.009 *

Also Published As

Publication number Publication date
CN107002085A (zh) 2017-08-01
EP3191505A2 (fr) 2017-07-19
BR112017004181A2 (pt) 2017-12-05
EA201790365A1 (ru) 2017-07-31
MA40624A (fr) 2016-03-17
AU2015313756A1 (en) 2017-03-09
CA2958222A1 (fr) 2016-03-17
WO2016038625A2 (fr) 2016-03-17
AR101840A1 (es) 2017-01-18
JP2017528137A (ja) 2017-09-28

Similar Documents

Publication Publication Date Title
WO2016038625A3 (fr) Antigènes supérieurs du papillomavirus présentant des propriétés immunologiques supérieures et vaccin les contenant
MX2019003768A (es) Moleculas de enlace especificas de hpv.
PH12017500727A1 (en) Modified virus-like particles of cmv
CR20200461A (es) Método para tratar las enfermedades asociadas al vph
AU2017297757A1 (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
WO2010104749A3 (fr) Vaccins contre le cancer ciblés sur des cellules comportant des antigènes
WO2015142671A3 (fr) Vecteurs du virus de la grippe et leurs utilisations
EA201491171A1 (ru) Вещества, содержащие улучшенные генетические конструкции il-12, вакцины, иммунотерапевтические составы и способы их применения
EP4303229A3 (fr) Capacité améliorée de présentation de l&#39;antigène de lymphocytes t de récepteur d&#39;antigène chimérique (car) par l&#39;introduction conjointe de molécules de stimulation conjointe
EP3456339A3 (fr) Nouvelle immunothérapie contre plusieurs tumeurs, telles que le cancer du poumon comprenant le cancer du poumon non à petites cellules (nsclc)
MX2015008847A (es) Composiciones inmunogenicas de virus de influenza y usos de las mismas.
MX352338B (es) Anticuerpos neutralizantes del virus de la influenza a y usos de estos.
EP3792628A3 (fr) Procédés permettant de prédire l&#39;utilité de néoantigènes pour l&#39;immunothérapie
MX349657B (es) Composiciones de vacuna de matriz de proteína que incluyen policationes.
AR080585A1 (es) Vacunacion contra tumores que comprende una respuesta inmune humoral contra proteinas propias
WO2016073595A8 (fr) Cellules t et cellules dendritiques pour le traitement du virus du polyome
WO2015195218A8 (fr) Particules pseudo-virales (ppv) grippales polyvalentes, et leur utilisation comme vaccins
WO2016191641A3 (fr) Procédés pour améliorer des réponses immunitaires spécifiques à un antigène à l&#39;aide d&#39;une polythérapie comprenant des antigènes de capside de papillomavirus
PH12021550521A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
EP4286002A3 (fr) Vaccins à particules pseudo-virales (vlp) de parvovirus canin (cpv) et utilisations associées
MY189495A (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
EP3515482A4 (fr) Association de nouveaux vaccins contre le virus zika et constructions d&#39;anticorps anti-adn destinées à être utilisées contre le virus zika
WO2015184403A3 (fr) Anticorps anti-récepteurs du facteur de croissance épidermique (egfr)
PH12014501795A1 (en) Rota virus subunit vaccines and methods of making and use thereof
WO2010048394A3 (fr) Vaccin contre le virus de la peste équine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15808033

Country of ref document: EP

Kind code of ref document: A2

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2958222

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2017513424

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2015313756

Country of ref document: AU

Date of ref document: 20150911

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201790365

Country of ref document: EA

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017004181

Country of ref document: BR

REEP Request for entry into the european phase

Ref document number: 2015808033

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015808033

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 112017004181

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20170302